Cuesta Martínez, ÁngelSainz-Pastor, NoeliaBonet, JaumeOliva, BaldomeroÁlvarez-Vallina, Luis2024-01-122024-01-122010Cuesta AM, Sainz-Pastor N, Bonet J, Oliva B, Alvarez-Vallina L. Multivalent antibodies: when design surpasses evolution. Trends Biotechnol. 2010;28(7):355-362. doi:10.1016/j.tibtech.2010.03.0070167-779910.1016/j.tibtech.2010.03.007https://hdl.handle.net/20.500.14352/92799Evolutionary pressure has selected antibodies as key immune molecules acting against foreign pathogens. The development of monoclonal antibody technology has allowed their widespread use in research, real-time diagnosis and treatment of multiple diseases, including cancer. However, compared with hematologic malignancies, solid tumors have often proven to be relatively resistant to antibody-based therapies. In an attempt to improve the tumor-targeting efficacy of antibodies, new formats with modified, multivalent properties have been generated. Initially, these formats imitated the structure of native IgG, creating mostly monospecific, bivalent antibodies. Recently, novel trivalent antibodies have been developed to maximize tumor targeting capabilities through enhanced biodistribution and functional affinity. We review recent advances in the engineering of multivalent antibodies and further discuss their promise as agents for invivo diagnostics and therapy.engjournal article1879-3096https://doi.org/10.1016/j.tibtech.2010.03.007https://www.sciencedirect.com/science/article/pii/S0167779910000557?via%3Dihubrestricted access612.017Ciencias Biomédicas24 Ciencias de la Vida